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Abbreviations: 
 
 
BMI-SDS   Body mass index Standard deviation score (z score ) 
DKA    Diabetic ketoacidosis 
GAD    glutamic acid decarboxylase 
GDM    gestational diabetes mellitus 
HbA1c    glycated haemoglobin 
HLA    human leucocyte antigen 
IFG     impaired fasting glucose  
IGT     impaired glucose tolerance 
MODY    maturity onset diabetes of the young 
OGTT    oral glucose tolerance test 
T1DM    type 1 diabetes 
T2DM    type 2 diabetes mellitus 
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THE EPIDEMIOLOGY AND INCIDENCE OF TYPE 1 DIABETES  
 
 
 
I. INTRODUCTION 
 
Diabetes mellitus is a complex multifactorial and heterogeneous syndrome characterized by 
hyperglycaemia resulting from inadequate insulin secretion and/or insulin action. Several 
pathogenic processes ranging from autoimmune destruction of the β-cells of pancreas to 
abnormalities that result in resistance to insulin are involved in the development of diabetes. 
The chronic hyperglycaemia of diabetes is associated with long-term complications including 
cardiovascular disease, renal disease, peripheral neuropathy, visual abnormality and 
dermatologic problems. Diabetes mellitus represents a huge burden to the individual, the 
family and to the society. Furthermore, as its rate has reached an alarming proportion 
worldwide, diabetes is a disease of great public health importance. 
 
 
1. Classification of diabetes 
The new classification proposes that hyperglycaemia, regardless of the underlying cause, can 
be subcategorized as follows: insulin-requiring for survival, insulin-requiring for control (i.e., 
for metabolic control, not for survival), not insulin-requiring (i.e. with treatment by non-
pharmacological methods or drugs other than insulin). IGT is now categorized as a stage in 
the natural history of disordered carbohydrate metabolism. IGT is coupled with impaired 
fasting glucose (IFG) (6.1-7.0 mmol/l). 
 5 
 
The classification of diabetes includes four clinical classes: type 1 diabetes, type 2 diabetes,  
other specific types of diabetes and gestational diabetes. 
 
 
Table 1 - Etiologic classification of diabetes mellitus based on the report of the Expert 
Committee on the Diagnosis and Classification of Diabetes (1) 
 
 
I. Type 1 diabetes (β-cell destruction, usually leading to absolute insulin deficiency) 
   A. Immune mediated 
   B. Idiopathic 
II. Type 2 diabetes (may range from predominantly insulin resistance with relative insulin 
     deficiency to a predominantly secretory defect with insulin resistance) 
III. Other specific types 
   A. Genetic defects of β -cell function (MODYa, mitochondrial diabetes…) 
   B. Genetic defects in insulin action 
   C. Diseases of the exocrine pancreas (pancreatitis, cystic fibrosis, hemochromatosis...) 
   D. Endocrinopathies (acromegaly, Cushing’s syndrome, pheochromocytoma...) 
   E. Drug- or chemical-induced (glucocorticoids, thyroid hormone, thiazides…) 
   F. Infections (congenital rubella, cytomegalovirus...) 
   G. Uncommon forms of immune-mediated diabetes (anti–insulin receptor antibodies…) 
   H. Other genetic syndromes sometimes associated with diabetes (Down syndrome...) 
IV. Gestational diabetes mellitus (GDM) 
 
a
MODY: maturity onset diabetes of the young 
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1.1 Type 1 diabetes 
Nowadays, we may subdivide T1DM in three groups from the etiological point of view: 
autoimmune, idiopathic and double. The autoimmune group is represented by: type 1A, which 
is polygenic and it is the most frequent type of this disease, corresponding to approximately 
80-90% of all T1DM cases. LADA (latent autoimmune diabetes in the adult), the other 
subtype of this group is a slowly progressive form of type 1 diabetes and is characterised by 
GAD antibody (anti-GAD) positivity, older age at onset, less ketosis-proneness and no 
immediate (for at least 6 months) insulin needs (2). Type 1B, also called idiopathic, has all the 
clinical features of type 1A, but the autoimmune component is not detected (3). 
Finally, the denomination of mixed, 1.5 or double (type 1 plus type 2) diabetes has been 
proposed when we have the type 1A (autoimmunity) plus type 2 (obesity, insulin resistance, 
dyslipidemia) diabetes characteristics in the same individual (4). 
 
Type 1 diabetes is broadly seen as a form of diabetes requiring insulin therapy. But the severity 
of metabolic features, both before and at the diagnosis of type 1 diabetes, is wide ranging. 
Diabetes-associated autoantibodies are not sufficient to define a categorical disease phenotype; 
patients who progress towards insulin requirement are characterized not only by 
autoantibodies but also by younger age at diagnosis, lower endogenous insulin secretion, 
leaner body mass and high HbA1c at the time of diagnosis (Figure 1). It is the juvenile-onset 
classic type 1 diabetes which is occupying one end of a spectrum as the most genetically 
determined and severe form of the disease. 
 
 7 
 
          
         IMMUNITY    AGE        GENES          BMI      INSULIN THERAPY 
T1DM 
in children 
 
 
T1DM 
in adults 
 
 
LADA 
 
 
T2DM 
 
 
Figure 1 - The spectrum of diabetes encompasses variable risk according to type of diabetes 
for immune changes, age at presentation, HLA genetic susceptibility, obesity (as body mass 
index), and insulin therapy (5) 
 
 
Type 1 diabetes (T1DM) is perceived as a chronic immune-mediated disease characterized by 
selective loss of insulin-producing β-cells in the pancreatic islets in genetically susceptible 
individuals. Based on histological studies of pancreas specimens from patients with new-onset 
type 1 diabetes, beta cell mass is reduced by ~ 80-90% at the time of clinical manifestation of 
the disease (6, 7). 
The appearance of autoantibodies in the prediabetic phase prior to the onset of immune-
mediated type 1 diabetes is the first detectable sign of emerging β-cell autoimmunity. There 
are five disease-related autoantibodies that have been shown to predict clinical T1DM (8, 9). 
These include classical islet cell antibodies (ICA), insulin autoantibodies (IAA), autoantibodies 
to the 65 kD isoform of glutamic acid decarboxylase (GADA), the protein tyrosine 
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phosphatase-related IA-2 molecule (IA-2A) and the zink transporter autoantibodies (ZnT8A). 
These autoimmunity markers can be used to identify at-risk subjects during the prodromic 
phase when autoimmune intervention is most likely to be effective and may also be therapeutic 
agents in their own right. The duration – months, years or even decades of the pre-clinical 
phase may vary according to the intensity of the pathologic process and beta cell repair (9, 
10). 
Several genes involved in the aetiology of type 1 diabetes have already been identified, but we 
still have little idea of the etiologic mechanisms that trigger autoimmunity and promote 
progression to disease. Type 1 diabetes may develop at any age but displays a marked age-
dependent heterogeneity in the severity of clinical presentation (11, 12). Past descriptions 
depict type 1 diabetes as a disease of childhood and early adulthood, however, more recent 
data suggest that only about 50–60% of those with type 1 diabetes are younger than 16–18 
years at presentation and that such disease occurs at a low incidence level throughout 
adulthood (11-13).  
 
1.2 Type 2 diabetes 
Type 2 diabetes, which accounts for 90–95% of those with diabetes encompasses individuals 
who have insulin resistance and usually have relative (rather than absolute) insulin deficiency. 
The disease is heterogeneous in terms of genetic, metabolic and clinical characteristics.  
Since the 1990s the incidence of type 2 diabetes in children and adolescents has risen 
dramatically in some countries and ethnic groups, which – apart from the special genetic 
predisposition of some ethnic groups - mirrors growth in urbanization, economic development, 
and the associated increase in overweight and obesity. 
A Hungarian study (14) from 1989 to 2001 also reported rising incidence rates over time, with 
57% of T2DM cases and 77% of IGT cases being diagnosed in the last six years of the study 
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(14). It is important to note, however, that this was a clinic-based and not a population-based 
study. A more recent study using risk-stratified screening and OGTT in Hungarian children 
and adolescents (15) has described a 2.5 % prevalence of IGT, and a 0.35% prevalence of 
type 2 diabetes in high risk children (being overweight and having additional risk factors 
according to the ADA criteria).  
Overall, type 2 diabetes is characterised by an older age of onset, is frequently associated with 
obesity (with predominantly abdominal fat distribution) and lack of physical activity. 
 
1.3 Maturity-onset diabetes of the young 
The clinical characterisation of MODY established that diabetes could develop on a familial 
basis without the requirement of insulin resistance (16). Six MODY genes (HNF4A, GCK, 
TCF1, PDX1, TCF2) which, overall, are involved in ~85% of MODY cases (17). All six 
MODY genes are expressed in the beta cell, with glucokinase (encoded by GCK) serving as 
the glucose sensor that controls the set point for insulin secretion, and the rest acting as 
transcription factors regulating pancreatic beta cell development and final beta cell mass. 
  
 
2. Clinical presentation of diabetes 
 
The manifestation of diabetes may differ from patient to patient, according to the type of 
diabetes and age at onset. Affected patients generally have a preceding history of the classic 
symptoms of diabetes. The period of time from when abnormalities in glucose control can be 
identified until the development of symptoms generally is relatively brief. The classic 
symptoms of diabetes are polydipsia, polyuria, polyphagia, and weight loss. Re-emergence of 
bedwetting, nocturia, and a need to leave classes in school to use the bathroom are complaints 
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that suggest polyuria. The other typical presentation for children who have type 1 diabetes is 
metabolic deterioration into diabetic ketoacidosis (DKA), presenting with nausea, vomiting, 
dehydration, and lethargy. In certain situations, the diagnosis of diabetes should be considered 
in the absence of the classic symptoms (infant who presents with an acute febrile illness in 
whom a plasma glucose value obtained as part of a chemistry panel is elevated). Chronic 
hyperglycaemia in girls and in infants and toddlers of both genders commonly leads to perineal 
candidiasis. 
The rate of beta-cell loss postdiagnosis is highly variable and may depend in part on the 
aggressiveness of the type 1 diabetes disease process. This aggressiveness may be determined 
by several factors including underlying genetic predisposition, age of the patient, metabolic 
control, and may vary within individuals over the course of their diabetes. 
 
 
3. Immune markers of type 1 diabetes 
 
The initial evidence for autoimmunity in patients with type 1 diabetes came from 
immunofluorescence studies, which showed that a high percentage of sera from newly 
diagnosed type 1 diabetic patients reacted with pancreatic islet cells (islet cell cytoplasmic 
antibodies or ICA) (18, 19). Since then, a series of autoantigens have been identified in T1DM 
including insulin, glutamic acid decarboxylase (GAD65) (20), the protein tyrosine 
phosphatase-related islet antigen 2 (IA-2) (21), and most recently the zinc transporter 
Slc30A8 residing in the insulin secretory granule of the β-cell (22).  
Several studies have shown that β-cell autoimmunity may be induced early in life (23). Around 
4% of offspring of parents with type 1 diabetes in the BABYDIAB study and around 6% of 
genetically at-risk infants from the general population in the Finnish Diabetes Prediction and 
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Prevention (DIPP) study have developed islet autoantibodies by age 2 years (24, 25). Children 
who develop autoantibodies within the first 2 years of life are those who most often develop 
multiple islet autoantibodies and progress to type 1 diabetes in childhood (24). Autoantibodies 
do not exclusively develop before age 2 years, but children who develop autoantibodies later 
have a slower progression to multiple antibodies and type 1 diabetes (24). 
There is no consensus whether there is any primary autoantigen in T1DM. According to the 
suggestion of a recent article (26) in the beginning of the autoimmune process against 
pancreatic beta cells, we may have three or more antigens, but at the end, there are endless 
antigens which are activating the process, i.e., the greater the beta cell lesion, the more 
antigens are expressed, which will reactivate the process. This proposal covers a new concept 
for the natural history of T1A diabetes mellitus which, in its preclinical stage, would be 
characterized by a succession of relapses and remissions with interrelation between regulatory 
T cells and effectors cells, and regeneration of beta cells up to the moment when the 
percentage of beta cell destruction would no longer allow a proper insulin secretion, resulting 
in the expression of hyperglycaemia. Within this context, it becomes important to mention the 
low capacity of regeneration/neogenesis of beta cells mainly when they are exposed to 
hyperglycaemia, which is a stimulus metabolic factor to the insulin secretion, but it is also 
glycotoxic. When proper glycaemic control is instituted at the beginning of the disease, these 
cells have acquiescence and may to keep the levels of C peptide secretion for a additional 
period of time. 
Type 1B, also called idiopathic, has all the clinical features of type 1A, but the autoimmune 
component is not detected (3). 
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4. Genetics 
 
The importance of genetic components in the pathogenic process leading to type 1 diabetes is 
supported by the observed higher concordance rate of monozygotic twins compared to 
dizygotic twins, by the familial clustering of the disease and by ethnical differences in the 
incidence of type 1 diabetes (27, 28). The vast majority of individuals who develop type 1A 
diabetes do not have a first degree relative with the disorder (>85%). Extending the ability to 
identify extreme risk to the general population without a relative with type 1A diabetes is thus 
an important goal. 
The risk of complex diseases such as type 1 diabetes is generally thought to be influenced by 
multiple genetic and non-genetic factors, and it has been hypothesised that interactions 
between genes, or epistasis, are very common for such diseases (29). There are now at least 
four genetic loci that are established as causally involved in the aetiology of type 1 diabetes. 
The major genetic susceptibility is encoded by specific allelic combinations of DRB1, DQA1 
and DQB1 in the human leucocyte antigen (HLA) complex. Variants in the insulin gene (INS), 
the cytotoxic T lymphocyte antigen-4 gene (CTLA4) and the protein tyrosine phosphatase, 
non-receptor type 22 gene (PTPN22) have been repeatedly associated with type 1 diabetes 
susceptibility using different approaches. All established loci are thought to be involved 
somehow in immune regulation, but details of the mechanisms relating the polymorphisms to 
risk of type 1 diabetes are in most cases poorly understood. 
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5. Environmental factors 
 
Environmental factors have been implicated in the pathogenesis of type 1 diabetes both as 
triggers and potentiators of beta-cell destruction (30-32). Studies in monozygotic twins 
suggest that only 13–33% are pairwise concordant for the disease (33, 34), which implies that 
there is either acquired postconceptional genetic discordance or differential exposure to 
putative environmental factors. The tenfold difference in incidence of children under the age of 
15 years reported in Europe with the highest incidence rate occurring in Finland (40.2/100000) 
and the lowest in Macedonia (3.2/100000) can hardly be explained by genetic factors (35). A 
considerable increase in the incidence of type 1 diabetes has been documented globally over 
the last decades, particularly in Europe (36). The steep increase cannot be exclusively due to 
an enhanced genetic disease susceptibility in the population but must mostly reflect changes in 
lifestyle and environment. Available data of migrant studies indicate that the incidence of type 
1 diabetes has increased in population groups who have moved from a low-incidence region to 
a high-incidence area, emphasizing the influence of environmental conditions (31). Studies on 
HLA genotypes demonstrated that the proportion of subjects with high-risk DR and DQ 
alleles has decreased over the last decades among patients with newly diagnosed type 1 
diabetes, whereas the proportion of people with low-risk or even protective HLA genotypes 
has increased (37, 38) suggesting the increase of the environmental pressure. 
Various exogenous triggers, such as certain dietary factors and viruses (39, 40), are thought to 
induce the immune-mediated process leading to extensive beta cell destruction and ultimately 
to the clinical manifestation of type 1 diabetes. Changes have occurred in multiple 
environmental conditions over the last half-century. These include perinatal factors (41, 42), 
increased weight gain in infancy (43, 44), sunlight exposure and vitamin D sufficiency (45), 
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dietary factors (46-48), use of pharmaceutical products (eg antibiotics), socioeconomic factors 
(49) and psychological factors (50), (51). 
 
 
6. Incidence of childhood type 1 diabetes 
 
During the last decades large international collaborative studies, using standardized 
ascertainment schemes have offered significant contributions to our knowledge of the global 
epidemiology of the disease. 
In 1983 an international meeting was held in Philadelphia, where the participating 
epidemiologists discussed the importance of establishing standardised registries to facilitate 
comparisons between countries. This meeting led to the birth of the Diabetes Epidemiology 
Research International (DERI) group. The DERI group played a key role in collecting 
standardised incidence data of T1DM between the late 1970s up to mid 1980s. Since then a 
lot of registries have been established all over the world.  
In 1988 the European Economic Community launched a study called EURODIAB ACE 
(Europe and Diabetes: Aetiology of Childhood Diabetes on an epidemiological basis) with the 
participation of 44 European centres to asses incidence of childhood T1DM in Europe, to 
gather information to determine the causes and pathogenesis of the disease (52) in children 
under the age of 15 years. The WHO Multinational Project for Childhood Diabetes 
(DIAMOND) was started in 1990. The DIAMOND network includes 112 centres from 57 
countries from around the world, representing about 84 million children with the data set of 
43013 children diagnosed between the years 1990 and 1999 (53). Wide variation in incidence 
of type 1 diabetes in children younger than 15 years has been well characterised by registry 
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reports from the EURODIAB study group within Europe and the DIAMOND project group 
worldwide. 
All of these registries have employed standardised protocols so that incidence data all over the 
world can be compared more effectively. Epidemiological data on type 1 diabetes are still 
lacking for the major part of the global population of children, especially in Africa, Asia, and 
South America (53). 
 
6.1 Type 1 diabetes worldwide 
It is estimated that on an annual basis some 76,000 children aged 14 years and under develop 
type 1 diabetes worldwide. In 2010, some 480000 children worldwide were estimated to have 
type 1 diabetes.  
24% of these newly diagnosed children come from South-East Asia and 23% come from 
Europe. 
 
Table 3 - Source: Diabetes Atlas 4
th
 edition International Diabetes Federation, 2009 
 
  Type 1 diabetes (0-14 ys)              2010 
  Child population                 1.9 billion 
  Number of children with type 1 diabetes         479000 
  Type 1 diabetes prevalence              0.02% 
  Annual increase of incidence             3.0% 
  Estimated number of newly-diagnosed cases per year     75800 
 
 
One of the most striking characteristics of childhood-onset T1DM is its huge geographical 
variation in incidence. According to the data of the DiaMond study the incidence level shows a 
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more than 350-fold variability across the populations studied between the years 1990 and 1999 
(53). Finland has the highest incidence of type 1 diabetes worldwide, reaching about 40 new 
cases per 100000 children at risk per year in the 1990s, whereas the Zunyi region in China was 
reported to have the lowest incidence with a rate of 0.1 cases per 100000 children at risk. 
Large intercontinental variation in incidence rates was also described (53); Figure 2). 
In most Asian populations the incidence was very low (less than 1/100000/year); except 
Kuwait, with a very high incidence of 22/100000/year. 
Among African populations, incidence was low or intermediate (1-9/100000/year). The 
incidence among South American populations varied between very low to high (1-
10/100000/year). In Central America and the West Indies, the range of variation was from 2 
to 17 /100000/year. In Oceania, the incidence of Type 1 diabetes was high or very high (14-
22/ 100000/year), reflecting difference in the ethnicity of populations within this region. The 
highest incidence rates were among European and North American populations varying from 
low to very high in Europe, (4-41 /100000/year) and from high to very high in North America 
(11- 25/100000/year).  
Europe has by far the most informative and reliable data. In Europe, a north–south gradient 
has been described (35, 52) in incidence, varying from the highest in Finland 
(43.9/100000/year) and other Scandinavian countries to the lowest in Macedonia 
(3.6/100000/year). Overall, the incidence rates were high in Northern and North Western 
Europe and low in Central, Southern and Eastern Europe (35), (Figure 3). Sardinia as an 
outlier being 3000 km south of Finland was an exception to this pattern with a five to seven 
times higher incidence rate than continental Italy (54).  
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Figure 2 – Incidence rates of type 1 diabetes in children 0-14 years (cases/ 100000 
population/ year) Source: Diabetes Atlas 4
th
 edition International Diabetes Federation, 2009 
 
 
Countries in Central Europe such as Austria, Hungary seem to be medium-risk countries 
between the high-risk populations of the Nordic countries and the low-risk South-European 
countries. The incidence of type 1 diabetes diagnosed under 15 years in Hungary (as 
determined in 18 counties) is intermediate in Europe. The Hungarian incidence is similar to the 
values observed in our neighbouring countries Austria, Slovakia and Slovenia. 
 
Sharp contrast in incidence can also be observed among neighbouring countries. Even within 
Scandinavia, with genetically homogenous populations, equally developed societies and at the 
same latitude, there are differences in incidence rates varying between Finland 
(42.9/100000/year, 1980-2005) (55), Denmark (22/100000/year, 1996–2000) (56), Iceland 
(19/100000/year, 2001–2005) (57), and Sweden (28.9/100000/year, 1983-2000) (58). 
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Finland and Sweden lie on the northern and eastern side of the Baltic Sea. Estonia lies to the 
east of the Baltic sea and despite of its similar language and genetic background to that in 
Finland (37.7/100000/year) Estonia has a considerably lower incidence (11.2/100000/year) of 
type 1 diabetes (59). Latvia (6.9/100000/year) and Lithuania (7.2/100000/year) nearby Estonia 
have about five times lower incidence compared with Finland (59). In marked contrast Poland 
south of the Baltic Sea has a comparable incidence rate (7.6/100000/year) to Lithuania in the 
age group 0-14 during 1987-1999. 
 
 
 
Figure 3 -  Variation in incidence of type 1 diabetes in children aged 0-14 years in Europe 
(60) 
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6.2 Within-country variation 
Within-country variation in incidence rate was observed in the Scandinavian countries such as 
in Sweden (61), Finland (62), in England (63), Italy (64) and Sardinia (65). Furthermore, 
studies in Finland (66), Sweden (67), Scotland (68) and Northern Ireland (49) have shown a 
higher incidence in rural than in urban areas. In contrast, reports from Lithuania (69) and Italy 
(64) have shown the opposite. 
Geographical variations in incidence rates of T1DM in children may be associated with the 
different distribution of socioeconomic factors between urban and rural area, population 
density and ethnic differences. 
 
6.3 Ethnicity 
The incidence of T1DM shows remarkable variations between races and ethnic groups, the 
risk being much greater among Caucasians, less in Blacks and extremely low in Asians and 
Pacific Islanders and correlates strongly with the variability in incidence across countries. 
According to the results of the largest population-based study in the US (SEARCH) the 
incidence of T1DM was highest among non-Hispanic white children (18.6 for 0-4 years;  28.1 
for 5-9 years; 32.9 for 10-14 years), followed by African American (9.7 for 0-4 years;  16.2 
for 5-9 years; 19.2 for 10-14 years) and Hispanic youth (9.1 for 0-4 years; 15.7 for 5-9 years; 
17.6 for 10-14 years), and lowest among American Indian (4.1 for 0-4 years; 5.5 for 5-9 years; 
7.1 for 10-14 years) and Asian/Pacific Islander youth (6.1 for 0-4 years; 8.0 for 5-9 years; 8.3 
for 10-14 years) (70). 
A recent migration study, carried out among German residents, comparing the incidence of 
German children versus Italian children originating from a very high-risk region (Sardinia) and 
from medium-risk areas (continental Italy) showed that children from Italy had incidence rates 
of T1DM that are closer to those of their native regions than to those of German children (71). 
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This finding indicates that genetic factors play a predominant role in the pathogenesis of 
T1DM. 
Muntoni et al. found that Sardinian-heritage children living in a region with low incidence 
(Lazio, Lombardy) still maintain a much higher incidence of the disease relative to non-
Sardinian children in the host region which is consistent with a stronger genetic susceptibility 
predominating over environmental factors (72). 
The incidence of T1DM in Asian and Pacific Islanders is very low. Monozygotic twins and 
first degree relatives of patients with T1DM in Japan had a similar risk of diabetes to twins and 
relatives of patients in the United States, suggesting that most of the between-country 
variation in diabetes risk might relate to genetic differences rather than environmental factors 
(73). 
 
6.4 Seasonality 
6.4.1 Seasonality at diabetes onset 
The seasonality at type 1 diabetes onset with a peak incidence in colder months and a nadir in 
warmer months has been extensively studied previously. Although many studies have found 
evidence for seasonality (74, 75), others have not (76) and some studies only found seasonality 
in population subgroups (77). The EURODIAB Study has shown heterogeneity in the 
seasonal pattern at type 1 diabetes onset according to age and region: seasonality was less 
pronounced in children diagnosed under 5 years and in Scandinavian countries. 
The incidence of type 1 diabetes is generally highest in older age groups which may explain 
that the seasonal pattern is more often found in older children. A recent study (78) with the 
participation of 105 centres also demonstrated a global seasonal pattern at diagnosis of  type 1 
diabetes. This seasonality pattern appears to be dependent on the geographical position, at 
least as far as the northern ⁄ southern hemisphere dichotomy is concerned. 
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This seasonal variation has been taken as an indirect argument in favour of the role of 
environmental factors – such as viral infection, average daily ultraviolet B (UVB) radiation – 
in the development of the disease. One must remember, however, that the autoimmunity, 
which leads to clinical diabetes is a long process, therefore, the environmental factors 
associated with seasonality can only be considered as disease precipitators acting at a late 
stage of prediabetes. 
6.4.2 Seasonality of birth 
Several epidemiological studies (79, 80)  have reported a seasonal pattern of birth, with a 
generally higher incidence for those born in spring and summer, than for those born in autumn 
and winter (81, 82), but little evidence have been found to support the hypothesis that seasonal 
environmental factors operating during fetal neonatal life have any influence on the 
development of type 1 diabetes in future life (83).  
 
6.5 Age 
T1DM is the major type of diabetes in youth, accounting for 85% or more of all diabetes cases 
in youth less than 20 years of age worldwide. The incidence increases from birth and peaks 
during puberty. The increasing incidence of T1DM throughout the world is especially marked 
in youngest children (0-4 years). Incidence rates decline after puberty especially in women but 
remains relatively high in young adult males up to the 29–35 yr of age (13, 84).  
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6.6 Gender 
Although data from various regions suggest a slight male excess in populations of high 
(23/100000/year<) incidence and a minor female excess in low-incidence populations, on 
average both genders carry similar risks. With an increasing incidence of T1DM the sex ratio 
appears to shift from a female excess to a male excess (85). Male excess has been observed in 
populations of European origin while slight female predominance has been reported in African 
or Asian populations (13, 84). 
 
6.7 Temporal trends in the incidence of T1DM 
The incidence of childhood-onset type 1 diabetes exhibits remarkable temporal variation 
concerning secular trends. Reports from the cumulative data from the large international 
collaborative incidence registration systems have consistently found that since about 1990 the 
incidence of childhood-onset type 1 diabetes has been rising globally (35, 53, 60), with the 
possible exemption of Central America and West Indies (53). 
According to the latest report from EURODIAB (60), in Europe the overall annual increase in 
incidence is 3.9% (ranging from 0.6% to 9.3%) during 1989-2003. The most striking changes 
with the steepest increase are observed in Central and Eastern Europe where the incidence is 
relatively low (Figure 4). These increases may result in a tendency for regional differences in 
European incidence rates to become less pronounced.  
The rise in incidence is most pronounced in youngest children aged 0-4 years with an annual 
rate of 5.4% compared to 4.3% in the age group 5-9 years and 2.9% in 10-14 years old 
children (60). 
In 2005 in Europe, the estimated number of newly diagnosed children with type 1 diabetes 
aged 0-14 years was 15000 and expected to increase to 24400 in 2020. Due to the sharp 
increase observed in youngest children, it is predicted that the percentage distribution of new 
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cases across the three age-groups will be more uniform at 29% (0–4 years), 37% (5–9 years), 
and 34% (10–14 years) compared to the ratios of 24% (0-4 years), 35% (5-9 years) and 41% 
(10-14 years) observed in 2005 (60).  
The lifetime incidence is probably stable with incidence increasing in children and decreasing in 
adults (86).  
 
 
 
Figure 4 - Inverse association between rate of incidence increase and average incidence 
Incidence rate on horizontal axis, plotted on a logarithmic scale. Spearman rank correlation 
coefficient rs=–0.52, p=0.02 (60) 
Average incidence rate 1989-2003 (per 100,000)
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II. AIMS 
Our study had two main aims. First to analyse the incidence of type 1 diabetes in the age 
group 0–14 years in Hungary for the period 1989–2009, second to ascertain the spectrum of 
severity of presentation, the prevalence of diabetic ketoacidosis at diagnosis of diabetes, and 
the potential predictors of DKA. 
 
INCIDENCE OF TYPE 1 DIABETES IN CHILDREN (0-14 YEARS) IN HUNGARY  
 
1. Incidence trends over time 
1.1 To evaluate whether the previously described increase in incidence observed between 1978 
and 1998 has continued. 
1.2. To predict future trends 
2. Gender, age-group specific incidence  
2.1 To analyze gender difference 
2.2 To analyze age-group specific incidence 
3. Seasonality 
3.1 To investigate whether the seasonal pattern of clinical onset of type 1 diabetes is a general 
characteristic or it is restricted to gender and/or age at diagnosis subgroups.  
4. Regional differences in incidence 
4.1 To investigate any regional differences among counties in Hungary 
4.2 To examine if population density was associated with incidence of type 1 diabetes 
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CLINICAL CHARACTERISTICS OF TYPE 1 DIABETES AT TIME OF DIAGNOSIS 
IN HUNGARIAN CHILDREN (2002-2009) 
 
1. Clinical and biochemical characteristics at time of diagnosis during 2002-2009 
1.1 To determine clinical characteristics at onset of type 1 diabetes in children aged 0-14 years 
1.2 To investigate gender and age group specific differences in clinical and biochemical 
characteristics 
1.3 To separately evaluate disease onset in subjects presenting with type 1 diabetes before 
their second birthday during the period from 2002 to 2009 
2. Diabetic ketoacidosis 
2.1 To investigate the frequency of diabetic ketoacidosis at type 1 diabetes onset, to analyze 
temporal trends and any regional differences in the occurrence of DKA 
2.2 To compare clinical characteristics of children presenting with and without DKA  
2.3 To identify predictors of diabetic ketoacidosis in newly diagnosed children under 15 years 
of age in Hungary 
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III. INCIDENCE OF TYPE 1 DIABETES IN CHILDREN (0-14 YEARS) IN 
HUNGARY 
 
 
Study design 
The Hungarian Childhood Diabetes Register has been collecting data of all newly diagnosed 
children with type 1 diabetes under the age of 15 years since 1978. Data for the first 11 years 
(1978–1988) were collected retrospectively. Prospective registration as part of the 
EURODIAB Study started in 1989 (52). I have been the data manager of the database from 
the beginning of the prospective data collection, and I have performed the statistical analyses. 
The study included the data of 18 counties. Budapest, the capital, and county of Pest were 
excluded from our study because historically we have found that the ascertainment level was 
low (87). There are several paediatric departments in the capital, and some of them - 
particularly in the first years of the registry - were unable to provide reliable case data. The 
ascertainment level has considerably improved in recent years and incidence data for the last 
year are now available for the capital, as well (vide infra). The children's population of 
Budapest is about one fourth of national total. The Hungarian population aged 0–14 years in 
18 counties decreased by one third from 1579450 (1989) to 1052184 (2009) during the study 
period. 
Type 1 diabetes mellitus was defined on the basis of a clinical diagnosis of idiopathic diabetes 
by a physician. Cases secondary to other conditions (eg. having cystic fibrosis or high-dose 
steroid treatment or MODY diabetes) were excluded. Date of onset was defined as the date of 
the first insulin injection. 
All cases on the register were included in the analysis if they were diagnosed between the 1 
January 1989 and 31 December 2009. The capture–recapture methodology, which assumes 
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that independent primary and secondary sources of ascertainment are available, was used to 
estimate the completeness of registration. In Hungary, children with new-onset diabetes aged 
0–14 year are hospitalized in paediatric departments at the time of diagnosis. Hospital case 
records served as primary source of ascertainment. The list of children who attended diabetes 
summer camps was used as an independent secondary source of ascertainment. These camps, 
organized by trade unions and later by charity organizations, were open to all diabetic children. 
Ascertainment was above >95% throughout the 21-year period with a uniform pattern over 
time: 1989-1993, 97.9%; 1994-1998, 95.9%; 1999-2003, 97.5%; 2004-2009, 100%.   
All denominators for incidence calculations were provided annually by the Central Bureau of 
Statistics. 
 
Statistical methods 
Annual end-year population estimates were used as denominators for calculation of rates. 
Age- and sex-standardized incidence rates were obtained using the direct method with a 
standard population consisting of equal numbers of children in each of the six subgroups 
defined by age group (0–4y, 5–9y and 10–14y) and gender. Confidence intervals for rates 
were calculated assuming that the observed number of cases followed a Poisson distribution. 
Poisson regression models were used to assess time trends in incidence. Models with terms for 
age group, gender and calendar year were fitted. Interactions were fitted to assess if the trends 
differed significantly between age groups or genders. Cyclic behaviour in the incidence trend 
was estimated by a Poisson regression model as described by Edwards JH (88). Heterogeneity 
between counties was assessed using Poisson regression. Population density was calculated by 
dividing the population by the geographical area (in square kilometres). 
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Predictions for future new cases until 2030 were made by extrapolating rates using the annual 
percentage increase in incidence in each age/sex subgroup estimated from the Poisson 
regression model. 
Statistical analyses were performed using STATA release 8.0 (Stata Corporation, College 
Station, TX, USA). 
 
Results 
THE AVERAGE STANDARDIZED INCIDENCE RATE 
A total of 3432 patients (1777 boys; 1655 girls) under the age of 15 years were registered 
during the observation period. 
The average standardised incidence rate was 12.5 (95%CI 12.0-12.9) per 100000 per annum 
over the 21 years, 12.6 (95% CI 12.0-13.2) in boys and 12.3 (95% CI 11.72-12.9) in girls. 
The age-specific incidence rates were 8.8 (95% CI 8.2-9.5), 13.5 (95% CI 12.7-14.3) and 
15.1 (95% CI 14.3-15.8) per 100000 person years in the 0-4, 5-9 and 10-14 year age groups, 
respectively.  
INCIDENCE TREND 
The incidence increased from 7.7 (95%CI 6.3-9.0) per 100000 person years in 1989 to 18.2 
(95%CI 15.7-20.9) in 2009 (Figure 5).  
Table 4 shows the mean age- and sex-specific incidence rates by three 5 year and one 6 year 
periods. The increase in incidence rate for the entire cohort (and in both sexes and in all three 
age groups) was highest between the periods 1999-2003 and 2004-2009. 
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Figure 5 - Age-standardised incidence rate (with 95% confidence intervals) for type 1 
diabetes in children aged 0-14 years in Hungary for each year in the period 1989-2009 with 
fitted log-linear trend.  
 
 
Table 4 - Age- and sex-specific incidence rates of type 1 diabetes in Hungary during 1989-
2009; incidence per 100 000 per year (95% CI) by three 5-year and a 6-year periods 
 
 
 1989-1993  1994-1998 1999-2003 2004-2009 
Boys 0-4 5.1 (3.8-6.4) 8.0 (6.3-9.7) 8.3 (6.4-10.1) 14.3 (12.0-16.6) 
 5-9 9.7 (7.9-11.4) 10.4 (8.5-12.2) 12.7 (10.6-14.9) 21.1 (18.4-23.8) 
 10-14 11.5 (9.8-13.3) 12.4 (10.4-14.4) 16.6 (14.3-18.9) 22.4 (19.8-25.0) 
      
Girls 0-4 5.4 (4.0-6.7) 7.2 (5.5-8.8) 9.5 (7.5-11.6) 13.8 (11.5-16.1) 
 5-9 9.4 (7.6-11.2) 12.1 (10.1-14.2) 13.8 (11.6-16.1) 19.9 (17.2-22.6) 
 10-14 13.0 (11.1-14.9) 13.9 (11.7-16.0) 13.5 (11.4-15.7) 17.7 (15.5-20.1) 
      
Boys&Girls 0-4 5.2 (4.3-6.3) 7.6 (6.5-8.9) 8.9 (7.5-10.3) 14.1 (12.6-15.9) 
 5-9 9.5 (8.3-10.8) 11.3 (9.9-12.7) 13.3 (11.8-14.9) 20.5 (18.6-22.5) 
 10-14 12.3 (11.0-13.6) 13.1 (11.7-14.6) 15.1 (13.6-16.8) 20.1 (18.3-21.8) 
      
Stand 
incidence 
 9.0 (8.4-9.7) 10.6 (9.9-11.5) 12.4 (11.6-13.3) 18.3 (17.3-19.4) 
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Results of the Poisson regression analysis are summarized in Table 5. This analysis 
demonstrated a highly significant linear trend in incidence over the 21-year period (line 1, 
Table 5). Fitting of a quadratic term in year showed no evidence of significant departure from 
linearity in the secular trend (line 2, Table 5). Interestingly, the year 2004 is an outlier with its 
unusually high incidence rate and 95%CIs above the estimated trendline, although rates for the 
years 2005 and 2006 are also above the linear prediction (Figure 5). There was also evidence 
of a significant difference in the trends between age groups (line 3, Table 5) and between 
genders (line 4, Table 5) with rates increasing faster in the younger age-groups and in boys. 
However, the test for interaction (line 5, Table 5) did not detect any significant difference 
between boys and girls in the patterns of increase by age-group.   
 
 
Table 5 - Summary of Poisson regression analyses fitted to data in 3 age groups, 2 sexes and 
21 years 
 
 
 
 
Model 
  
Likelihood ratio 
test 
on last model term 
Goodness-of-fit 
test 
  -2log L  χ
2    
 df P           χ2 df P 
0 A+S+A•S 1020.37     381.97 120 <0.001 
1 A+S+A•S+Y 784.34  236.04 1 <0.001 145.93 119 0.05 
2 A+S+A•S+Y+Y2 784.23  0.11 1 0.74 145.82 118 0.04 
3 A+S+A•S+Y+Y•A 769.19  15.14 2 0.001 130.79 115 0.15 
4 A+S+A•S+Y+Y•A+Y•S 763.37  5.82 1 0.016 124.97 116 0.27 
5 A+S+A•S+Y+Y•A+Y•S+Y•A•S 760.36  3.01 2 0.22 121.96 114 0.29 
          
          
 A -  Age, S - Sex,          
 
Y -  linear term in year,  
Y
2
 - quadratic term in year,         
 Y•A - Interaction between Y and A         
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Table 6 shows that there was an average annual increase of 4.4% (95%CI 3.9-5.0; p<0.001) 
after adjustment for age and sex.  
 
 
Table 6 - Summary of Poisson regression analyses showing age-and sex-specific annual 
increases (95% CI) expressed as % during 1989-2009 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 shows that the increase was evident in both genders with higher rates for boys (5.1%, 
95% CI 4.3-5.9; p<0.001) compared to girls (3.7%; 95% CI 2.9-4.6; p<0.001). Boys showed 
faster rates of increase in incidence of type 1 diabetes in all three age groups than did girls, but 
only in the oldest age-group was this difference significant (p=0.004), (Table 6). 
 Boys Girls        Boys & Girls 
    
0-4 y 6.4 (4.6-8.2)  6.0 (4.2-7.9)  6.2 (4.9-7.5)  
       
5-9 y 5.2 (3.8-6.6)  4.6 (3.2-6.0)  4.9 (3.9-5.9)  
       
10-14 y 4.5 (3.3-5.7)  1.9 (0.7-3.2)  3.3 (2.4-4.1)  
       
All ages 5.1 (4.3-5.9)  3.7 (2.9-4.6)  4.4 (3.9-5.0)  
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Figure 6 - Time trends in age-specific incidence rates in boys and girls plotted on a 
logarithmic scale for each year in the period 1989-2009.  
 
 
 
AGE- AND SEX SPECIFIC INCIDENCE RATES 
Figure 7 shows the age distribution of the incidence for girls and boys. The incidence peak for 
girls occurred 2 years earlier than the peak for boys. The incidence rate was similar in boys 
and girls at or before the age of 10 years, but thereafter it started to diverge (Figure 8). The 
overall boy-to-girl ratio in incidence was 1.02, 1.0, 0.97, 1.08 for the age groups 0-4 year, 5-9 
years and 10-14 years, respectively. 
         Boys                                                       Girls 
          0-4 yr 
          5-9yr 
          10-14 yr 
          0-4 yr 
          5-9yr 
          10-14 
yr 
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Figure 7 – Age specific and sex specific incidence rates per 100000 per year in Hungarian 
children 
 
 
INCIDENCE PREDICTION 
Assuming that the rates of increase observed in 1989-2008 continue, by 2030 the number of 
newly diagnosed children aged 0-14 years in Hungary is predicted to be 2460 with a 
distribution of 31% being in the 0-4 year, 38% in the 5-9 year and 31% in the 10-14 year age 
groups. The predicted age-specific incidence rates are 56 per 100000, 59 per 100000, and 43 
per 100000, respectively for the three age groups (Figure 8). 
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Figure 8 - Estimated and predicted incidence of newly diagnosed type 1 diabetes 
 
 
SEASONALITY AT DIAGNOSIS 
There was a clear seasonal variation over the year (χ2=72.8; p<0.001), with a peak in the 
winter months and a trough in the summer months (Figure 9).  
 
  
 
Figure 9 - a. Seasonality at first insulin injection in Hungary 
   b. Seasonality of first insulin injection by age groups during the period 1989 and 2009 
 The solid lines represent the observed values transformed into results for months of equal length. The 
 dotted lines represent the fitted sinusoidal trend. a 0–4 years: cyclic trend: χ2=0.56, p=0.76, b 5-9  years: 
 cyclic trend: χ2=26.1, p<0.001. c 10–14 years: cyclic trend: χ2=66.21, p<0.001 
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When the data were further analyzed by age groups, the seasonal variation was observed in the 
10-14 years age group (χ2=66.2; p<0.001) and in the 5-9 years old children (χ2=26.1; 
p<0.001) but not in the youngest children. January had the highest peak whereas June showed 
the lowest number of newly diagnosed children. The corresponding amplitudes of oscillation 
were + / - 3.9%, + / - 20.9% and + / - 29.6% for the age groups 0-4yr, 5-9yr and 10-14yr, 
respectively. 
 
REGIONAL DIFFERENCES 
There was evidence of a difference in age-standardised incidence rates among the counties 
(χ2=109.4; p<0.001).  
 
 
  
 
 
Figure 10 – Regional differences in incidence of type 1 diabetes in children aged 0-14 years in 
Hungary (1989-2009)  
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The addition of a year by region interaction term was not significant, indicating that the rate of 
increase did not differ among the counties. Counties in the western part of Hungary tend to 
have higher incidence rates than the overall average while the eastern part show lower 
incidence rates (Figure 10). Population density failed to show any significant association with 
incidence (r=0.02; p=0.94). 
 
Discussion 
The present study has reported the 21-year data of the Hungarian Childhood Diabetes Registry 
during 1989-2009 in a genetically stable, homogenous population using standard diagnostic 
criteria and epidemiological methods, with an ascertainment level of  >95% over the years. 
With the overall incidence rate of 12.5 per 100000 per year, which is comparable to the 
incidence in the surrounding countries (89-92), Hungary belongs to the medium incidence 
geographical regions. During the observation period the background population of children 
aged below 15 years has dropped by a third, and at the same time the number of newly 
diagnosed children increased considerably by around 40 new cases per year in boys and 20 
new cases per year in girls. These changes have resulted in the 2.4 fold increase in incidence of 
type 1 diabetes in Hungarian children during 1989-2009 exceeding the earlier prediction – 
based on the observed trend between 1989-1998 - of a doubling in incidence rates in 15 years 
(93). The incidence of type 1 diabetes increases with age, the peak is around puberty with the 
associated gender effect as at the beginning of the study period but because of the rapid 
increase in younger children the difference in incidence among the age groups seems to be 
diminishing; the incidence in the 5 to 9 year age group has now reached that of the 10 to 14 
year age group, particularly in females. Although our study has been restricted to children 
younger than 15 years of age, more data are becoming available about the incidence of type 1 
diabetes in young adults. According to these results the incidence rate decreases substantially 
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after the age of 15 years and seems to stabilize in young adults (15-29 years), although there 
are some indications of an increasing trend up to the age of 39 years. 
In more recent years a male excess in the age standardised rate has become evident compared 
to a female excess noted previously, and the Poisson regression analysis detected this 
difference in rates of increase between the sexes (93). 
The statistical analysis showed an overall increasing trend with little evidence of deviation 
from linearity. However, the year 2004 was an outlier with higher incidence than predicted 
compared to previous years and the subsequent periods, mainly because of the unexpectedly 
high number of new cases observed in the 5-9-year old males. The “peak” incidence in the year 
2004 was followed by stable rates for a number of years. We observed similar transient 
stabilization of incidence (at a lower level) between 1980 and 1984 (87). Some of the high risk 
countries have also shown no increase in incidence for brief periods over the last 20 years (94, 
95) . The latest report from Finland (55) shows strikingly stable rates between 1980 and 1987 
with subsequent steep increase. Recent publications from neighbouring Austria (91) and 
Croatia (90) have also reported transient periods of stabilization (1979 to 1989 and 1995 to 
2000, respectively), although the general trend remained clearly upward. When we compared 
the first 10-year period with the second 11 years we found that the increase was larger during 
1999-2009 (5.2% vs. 3.6% during 1989-1998) although the difference was not significant. 
Publications from the neighbouring countries of Hungary as well as other European 
populations reported similar increasing trends in incidence with accelerated increase in recent 
years (90, 91, 96-98). Although we found no evidence of systematic departures from log linear 
trends, in countries with high incidence where the rate of increase is less steep suggesting a 
levelling off compared to medium or low-incidence regions, a log linear trend may not always 
be appropriate (94, 99). Reports of stabilization of rates should therefore be interpreted with 
caution, particularly if they are based solely on visual impression of short-term changes in rates 
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or on the fitting of smoothed non-linear relationships that do not offer any significant 
improvement in model fit. The prevailing pattern seems to be one of continuing increase.  
Many attempts have been made to explain the rising trend in incidence over the past decades 
and several studies indicated the role of life-style-related risk factors (environmental 
exposures) such as high calorie intake, rapid early growth and rapid early weight gain (100-
103). It is of considerable significance that a recent publication from Sweden  reported a 
levelling off of incidence in birth cohorts from the year 2000 and thereafter (99) paralleling a 
decline in the prevalence of overweight and obesity in 4-year-old children. It is at present too 
early to know whether or not this new observation is an isolated phenomenon unique to 
Sweden or if it will generalize to other populations in due course. However, the claim that this 
represents a shift back to older age at onset (99) seems premature until data are available on 
the risks in this young cohort at older age-groups.  
Consistent with previous reports, we found a significant seasonal pattern at clinical diagnosis 
of type 1 diabetes, with peak values between January and March. The seasonal variation was 
comparable with a sinusoidal curve, and the observed amplitude of oscillation averaged 
±20.6%. Although the seasonal variation in the 10-14 age-group is well described as a 
sinusoidal pattern in Hungarian children this is not the case for the 5-9 age-group. In contrast 
to EURODIAB, our study failed to observe seasonal variation in the youngest age group, 
possibly due to a lower number of cases in this age group. It is interesting to note, that all age-
groups show a larger than expected number of cases diagnosed in October possibly due to 
return to school.  
Regional differences between continents, countries and areas within countries in incidence of 
type 1 diabetes have widely been observed. The finding of a higher incidence in rural areas 
compared to urban areas has been linked to a theory called “hygiene hypothesis”. According to 
this hypothesis, high-dense population urban areas with crowded households and higher 
 39 
 
infectious exposure in early life are expected to have lower incidence rates due to the 
protective effect of infections (104). A number of studies have supported this finding; the 
results are however, controversial. Although, the current analysis showed some evidence of 
difference in incidence among counties, no clear pattern has been identified. Furthermore, no 
association with population density could be confirmed. There were some indications that 
countries in the western part of Hungary have higher incidence rates compared to those lying 
in the Eastern part. More detailed analysis using small area units and including socioeconomic 
factors are needed to investigate any possible differences among areas.  
One possible limitation of our study is that Budapest and county of Pest covering about 25% 
of the children’s population were excluded for their low level of ascertainment. In 2010 we 
managed to collect more accurate data, which show that the incidence in Budapest 
(25.6/100000/year; 95% CI 19.3-33.3) and in county of Pest (18.6/100000/year; 95% CI 
13.1-25.5) was comparable with the national average incidence and we assume that it was 
similar in previous years.  
 
 
IV. CLINICAL CHARACTERISTICS OF TYPE 1 DIABETES AT ONSET IN 
CHILDREN AGED 0-14 YEARS IN HUNGARY 
 
Introduction 
Ketoacidotic episodes are still the most common causes of hospitalisation and deaths in 
children with type 1 diabetes and also seem to influence the longer term clinical course of type 
1 diabetes. Children with diabetic ketoacidosis at diagnosis have poorer glycaemic control, less 
residual β cell function up to two years after diagnosis (105, 106) and a lower frequency of 
remission (106, 107).  
 40 
 
Diabetic ketoacidosis at onset has been the subject of many investigations and reviews during 
the last decade. Although some studies have found that the clinical presentation at onset has 
become less severe with time (108, 109); there is no clear evidence that the prevalence of 
diabetic ketoacidosis at time of diagnosis has decreased over the past years (110, 111); in fact 
with increasing incidence of type 1 diabetes reported to be most remarkable in youngest 
children, an actual increase is anticipated.  
There were only isolated reports based on hospital records on the clinical characteristics of the 
disease in children (112-114), but no population-based study has been initiated so far to assess 
the frequency of diabetic ketoacidosis at time of diagnosis in Hungarian children. 
 
Study design 
Prospective registration of laboratory and clinical data at diagnosis as part of the Hungarian 
Childhood Diabetes Register has started in January 1, 2002. All children with new-onset type 
1 diabetes aged 0-14 years diagnosed between 1 January 2002 and 31 December 2009 were 
involved in our study.  
In order to investigate clinical characteristics at type 1 diabetes onset and to provide reliable 
information about the prevalence of diabetic ketoacidosis in Hungary I prepared a standard 
data sheet for prospective registration of clinical and laboratory data. Data collection using 
this new form (by e-mail and by post) from all paediatric diabetes centres started on 1
st
 
January, 2002. Information regarding the clinical presentation, duration (given as number of 
days) of symptoms prior to diagnosis observed by a parent (or reported by a child) and 
preceding infection were recorded. Level of consciousness (classified into three categories of 
normal, impaired consciousness and coma), hydration status (normal or dehydrated) were 
evaluated by the clinician examining the patient at the time of hospital admission. Weight and 
height at diagnosis was documented. BMI (kg/m2) was expressed as body mass index 
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standard deviation score (BMI-SDS) based on the national standard data of the longitudinal 
growth study by Joubert et al (115). Biochemical data were obtained before administering 
intravenous fluids or insulin at the hospital. Data were submitted continuously to the Central 
Coordinating Office, Department of Paediatrics, University of Pécs, Pécs, Hungary. Individual 
data were entered into a Microsoft Access database (set up and maintained by myself). 
Standard laboratory methods were used to measure serum glucose, HbA1c, electrolytes, blood 
urea nitrogen, venous blood gases and urinalysis. HbA1c was measured by HPLC (high-
performance liquid chromatography method) with a reference range of 4 to 6%.  
Ketoacidosis was defined as a blood pH less than 7.3. Ketoacidosis was categorized by 
severity of the acidosis, varying from mild with 7.3>pH≥7.2, to moderate with 7.2>pH≥7.1 l 
and severe with pH≤7.1. 
Positive family history was defined as having a first-degree relative with type 1 diabetes.  
 
Statistical methods 
Statistical analyses were carried out using SPSS for Windows (version 15.0, Chicago, IL). For 
normally distributed data results data were summarized as mean values ± standard deviations 
(SD). Unequally distributed results expressed as median and interquartile range (IQR) were 
analyzed by Kruskal-Wallis and Mann-Whitney U tests. Continuous variables were compared 
by the independent sample Student`s t- or one-way analysis of variance tests; categorical 
variables, using cross tabulation calculation. Univariate analyses were followed by a 
dichotomous (DKA yes/no) logistic regression model with forward, stepwise elimination 
methods, including all variables that showed p<0.10 on univariate analysis. Main effects and 
interaction effects were estimated. The Hosmer-Lemeshow method was used to assess 
goodness of fit. 
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Results 
Between 1 January, 2002 and 31 December, 2009, a total of 1558 newly diagnosed children 
(828 boys; 730 girls) were identified with type 1 diabetes. The mean age at diabetes diagnosis 
was 8.6±3.9 years (range 0.4-14.9); girls were significantly younger (8.3±3.8 years; p=0.02) as 
compared to boys (8.8±4.0 years). The mean blood glucose concentration was 26.5±11.9 
mmol/l (range 6.9-140mmol/l), the mean glycated haemoglobin (HbA1c) was 11.9±2.6 % 
(range 5.6-25.8%) at the time of diagnosis.  
 
CLINICAL CHARACTERISTICS AT TIME OF DIAGNOSIS 
3% of the children had no symptoms before diagnosis. The median duration of symptoms 
before diagnosis was 14 days (range 0-364). 514 (33%) children had duration of symptoms ≤7 
days, 4.6% of the children had symptoms over 2 months. Polyuria and polydipsia, the most 
frequent symptoms in all age groups were present in 89.2% of all cases (Figure 11). 7.9% of 
the children were reported to have impaired consciousness at diagnosis and 0.2% was 
considered unconscious. 296 children (19%) had an infection at diagnosis. Girls had 
significantly lower BMI-SDS compared to boys (-0.73±1.1 vs -0.55±1.1; p=0.002). Other 
clinical and biochemical characteristics at onset did not differ significantly between boys and 
girls. 
Blood pH ranged from 6.76 to 7.60 (mean±SD; 7.30±0.14). DKA (pH<7.3) was identified in 
32% of the children (n = 498), of which 44% had mild, 26% moderate, and 30% severe DKA. 
The highest prevalence of ketoacidosis occurred in more underweight children with a BMI-
SDS ≤ -1 (42% vs 32% with -1< BMI-SDS ≤ 0 vs 29% with 0< BMI-SDS ≤ 1 vs 19% with a 
1 < BMI-SDS; p<0.001). 
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Figure 11 – Clinical symptoms  
 
 
The frequency of DKA was similar over the years from 2002 to 2009 (p=0.29), ranging from 
30.2% in 2003 to 40.5% in 2008 (Figure 12).  
 
 
Figure 12 – Temporal trends in DKA rates of children aged 0-14 years with type 1 diabetes 
onset in Hungary (2002-2009) white columns: No acidosis, blue columns: mild DKA 
7.1≤pH<7.3, red columns: severe acidosis pH<7.1 (p=0.14) 
Frequency (%) 
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Comparison of clinical and biochemical characteristics of patients with DKA and those 
without DKA are shown in Table 7. Patients with ketoacidosis at onset were younger, had a 
significantly lower BMI-SDS, higher mean blood glucose and mean HbA1c level and one-
quarter of them had an acute infection at presentation. The occurrence of DKA was less 
frequent in children with a first degree relative of type 1 diabetes.  
 
 
Table 7 - Comparison of clinical and laboratory data of children according to metabolic status 
 
Clinical characteristics      DKA     No DKA     p  
Male (%)           263 (53)    497 (57)       NS
1
 
Age [year]           7.4±4.1    8.4±3.8     <0.001
2
 
Duration of symptoms days [(IQR)]   14 (7-22)   14 (7-28)       0.07
3
 
BMI-SDS           -0.9±1.1    -0.5±1.0     <0.001
2
 
Infection [%]          27.3     15.8      <0.001
1
 
Dehydration [%]         88.3     43.8      <0.001
1
 
Positive family history [%]      11.0     16.0         0.012
1
 
Blood glucose [mmol/l]       30.8±13.1   24.5±10.6    <0.001
2
 
HbA1c [%]           12.5±2.4   11.6±2.6    <0.001
2
 
 
Data are mean±SD or frequency or median (interquartile range). 
1
 Crosstabulations, 
2
 T-test, 
3
 Mann-Whitney U test 
 
 
COMPARISON OF CLINICAL CHARACTERISTICS ACCORDING TO AGE GROUPS 
351 children (22.5%) were aged 0-4 years, 553 children (35.5%) were aged 5-9 years and 654 
children (42%) were 10-14 years at diagnosis (χ2=91.7; p<0.001). Gender distribution of the 
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two younger age groups was similar; however in oldest children more boys compared to girls 
have been diagnosed (369 boys vs 285 girls; χ2=10.3; p=0.001). 
The median duration of symptoms before diagnosis was 14 days (range 7-2.5 days) and it was 
significantly shorter in youngest children [9 days (IQR 7-19) in 0-4yr vs 14 days (IQR 7-21) in 
the 5-9 yr vs 21 days (IQR 7-28) in 10-14yr; (χ2=60.9; p<0.001)]. Symptoms at presentation 
were similar in all age groups. Consciousness was more often impaired in the very young 
children (16.4% in 0-4 yr vs. 6.3% in 5-9 yr vs. 5.2% in 10-14 yr; p<0.001). A concomitant 
infection was more frequently observed in the youngest age group (31.5% in 0-4 yr vs. 19% in 
5-9 yr-, vs. 13.3% in 10-14 yr; χ2=40.7; p<0.001).  
Lower BMI SDSs compared with age matched reference data were found in all age groups 
(Table 8). Youngest children had gross hyperglycaemia with mean blood glucose close to 30 
mmol/l, while HbA1c was lowest in children aged 0-4 years, indicating a shorter duration of 
hyperglycaemia in this age group. The youngest age group had significantly lower BMI-SDS 
compared to older children. Patients in the age group 0-4-years had more severe acidosis 
compared to older children and about half of them had DKA (Table 8).  
Although, a decreasing frequency of DKA was observed with increasing age in both genders, 
there was an indication of the lowest frequency of DKA to be found around 5-6 years (Figure 
13).  
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Table 8 - Clinical and biochemical characteristics of children with newly diagnosed type 1 
diabetes according to age groups 
 
           0-4 years    5-9 years    10-14 years  p 
n (%)          351 (22.5)   553 (35.5)   654 (42)   <0.001 
Male (%)
§
        176 (50)    283 (51)    369 (56)    NS
1
 
Duration of symptoms (days)
 *
  9 (7-19)     14 (7-21)     21 (7-28)  <0.001
1
 
                            <0.001
2 
                               0.02
3
 
BMI-SDS           -1.04±1.3      -0.54±1.1      -0.51±1.0  <0.001
1
 
                            <0.001
2 
                              NS
3
 
Blood glucose (mmol/l)
 **
     29.4±13.1     26.0±11.0     25.4±11.6  <0.001
1
 
                            <0.001
2 
                              NS
3
 
HbA1c (%)
**
         10.9±2.2     12.0±2.6     12.3±2.6  <0.001
1
 
                            <0.001
2 
                              NS
3 
pH
**
              7.26±0.16      7.31±0.13      7.31±0.13 <0.001
1
 
                            <0.001
2 
                              NS
3
 
DKA, pH<7.30 (%)
§
       46.4       33.2       30.7    <0.001
1
 
                            <0.001
2 
                              NS
3
 
Severe DKA, pH<7.10 (%)
§
    17.2      9.8     7.9   <0.001
1
 
                            <0.001
2 
                              NS
3
 
Data are mean±SD or median (interquartile range) or frequency  
*
Mann-Whitney, 
**
 T-test,
 §
 Crosstabulations 
1
0-4yr vs 5-9 yr; 
2
0-4yr vs 10-14 yr; 
3
5-9yr vs 10-14 yr 
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 Figure 13 – DKA (pH<7.3) frequency in children with type 1 diabetes aged 0-14 years at 
diabetes onset in Hungary (2002-2009). 
 
 
CLINICAL CHARACTERISTICS IN CHILDREN AGED <2 YEARS 
From 2002 to 2009, a total of 94 (6.0%) patients were diagnosed before the age of 2 years 
and 257 (16.5%) patients were diagnosed between 2.0 and 4.99 years of age. Comparison of 
children aged <2 years at diagnosis with children aged 2.0–4.9 years is displayed in Table 9. 
There were no significant differences in the duration of symptoms and the presenting 
symptoms before diagnosis. Furthermore, there were no differences in the frequency of a 
preceding infection (37% children <2 yr vs 29.5% in 2.0-4.9 yr; NS) and a family history of 
type 1 diabetes between the age-groups.  
Frequency (%) 
Age at onset (year) 
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Table 9 - Clinical and biochemical characteristics of children with newly diagnosed type 1 
diabetes according to age groups 
 
              <2 years   2.0-4.9 years   p 
  Male (%)          49 (52)    127 (49)     NS
1
 
  BMI-SDS           -1.14±1.1      -1.0±1.4    NS
2
 
  Blood glucose (mmol/l)      32.1±16.2     28.3±11.7    0.04
2
 
  HbA1c           10.3±2.1     11.2±2.2    0.006
2
 
  pH              7.22±0.17      7.28±0.16.   0.007
2
 
  DKA, pH<7.30        59.3       41.2      0.003
1
 
  Severe DKA, pH<7.10      25.3       14.0      0.01
1
 
 
  Data are mean±SD or frequency 
  1
 Crosstabulations, 
2
 T-test 
 
 
The proportion of children with impaired consciousness tended to be higher in children aged 
less than 2 years (25% in children <2 yr vs 13.1% in 2.0-4.9 yr; χ2=8.53, p=0.01). Children 
aged <2 years had a significantly higher rate of DKA at presentation. 
 
RISK FACTORS OF DIABETIC KETOACIDOSIS 
The results of the univariate analysis and multiple logistic regression models used to examine 
the risk factors for DKA at diagnosis are shown in Table 9. Using logistic regression analysis, 
we found that children <2 years of age had two times the risk of presenting in diabetic 
ketoacidosis as children 10-14 years of age (Table 10). Children with lower BMI-SDS are 
more likely to present in diabetic ketoacidosis. Higher blood glucose and a history of infection 
were associated with an increased risk of diabetic ketoacidosis. Our study failed to show a 
significant association with a family history of type 1 diabetes. 
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Table 10 - Results of univariate and multivariate logistic regression analyses related to factors 
associated with diabetic ketoacidosis (pH<7.30) The analysis was performed with a binary 
logistic regression model using the reference levels as age group: 10–14 yr, infection status: no 
and family history: no. 
 
 
Variable       Univariate analysis    Logistic regression analysis 
  Adjusted Odds Ratio  
 (95% CI)    p value 
Age groups            0.02
1
 
<2 years                2.24 (1.3-3.7)       0.002 
2-4.9 years               1.2 (0.8-1.7)      0.3 
5-9.9 years               1.0 (0.8-1.4)      0.7 
Infection          <0.001
1
       1.7 (0.9-2.1)      0.001 
Blood glucose [mmol/l]       <0.001
2
       1.04 (1.03-1.05)   <0.001 
Duration of symptoms [weeks]      0.07
3
       0.95 (1.2-2.4)          0.06 
BMI-SDS          <0.001
2
       0.8 (0.7-0.9)    <0.001 
Positive family history        0.012
1
       0.7 (0.5-1.1)      0.1 
HbA1c [%]
 
         <0.001
2
 
Ketonuria          <0.001
1
 
Dehydration          <0.001
1 
 
1
 Crosstabulations;
2
 T-test; 
3
 Mann-Whitney U test  
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Discussion 
Our study showed that 30% of Hungarian children had DKA (pH<7.3) at diagnosis of type 1 
diabetes and 9.6% presented with severe DKA (pH<7.1) during the study period of 8 years, 
with no significant time trend over the years. 
This observed prevalence is somewhat higher than published in Sweden (116) and Finland 
(117) and comparable with recent and earlier results in other European countries (118-122) 
although the wide range of definition for diabetic ketoacidosis used in different studies makes 
the comparison difficult. 
The clinical pattern has not changed in the past few years; polydipsia and polyuria, the classic 
symptoms of diabetes as well as fatigue and weight loss were the most commonly reported 
symptoms. Although one-third of the children was reported to have duration of symptoms 
before diagnosis ≤ 7 days, the higher mean HbA1c level suggested that symptoms might have 
been present for a longer period without being recognized. Some studies found clear evidence 
that at least some children with diabetic ketoacidosis experienced diagnostic or treatment 
delays as up to a third of the children had at least one medical consultation in the week before 
diagnosis, and misdiagnosis was associated with a threefold increase in diabetic ketoacidosis. 
We failed to observe higher frequency/risk of DKA at onset in older children as recently 
reported by studies in Austria (120), Finland (117) and Germany (121). In agreement with 
other studies (120), younger age was associated with an increased risk of diabetic ketoacidosis 
at diagnosis. This increased risk was most noticeable in children less than 2 years old and 
disappeared by the age of 5 years. The reasons for this are probably multifactorial. DKA can 
easily be overlooked in younger children, since the classic symptoms of diabetes in this age 
group may be subtle and decompensation usually develops quicker as the mechanisms of 
metabolic compensation are less developed (108). On the other hand, β cell destruction may 
be more aggressive in young children: serum levels of proinsulin C peptide are lower in 
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children under 2 years old at time of diagnosis and they continue to lose their endogenous 
insulin secretory capacity faster than older children after diagnosis (122).  
Multiple factors affect the risk of developing diabetic ketoacidosis at the onset of type 1 
diabetes in children. In our study, younger age at diagnosis, history of preceding infection, 
lower BMI-SDS and higher blood glucose were the factors associated with increased risk of 
presenting with diabetic ketoacidosis at time of diagnosis. 
It is unclear why some children present in diabetic ketoacidosis whereas others do not and 
whether the development of diabetic ketoacidosis is a consequence of delayed diagnosis or 
whether it reflects a particularly aggressive form of diabetes. Understanding which factors are 
associated with diabetic ketoacidosis at diagnosis and the relative importance of delayed 
diagnosis and treatment is, therefore, important. 
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V. THESIS 
 
I. INCIDENCE OF TYPE 1 DIABETES IN CHILDREN (0-14 YEARS) IN HUNGARY  
Using the large database of a prospective registry, including 3432 incident cases, covering 
about 75% of the total 0-14 year-old population in Hungary we were able to study incidence 
trends with precise statistical methods over two decades. Crucial for time-trend analysis is a 
sustained high level of ascertainment over time. Ascertainment procedures show a consistently 
high ascertainment rate above 95%. The variability over time is thus assessed to be a 
maximum of 4%, which should not affect the time trend analysis in this age group. 
 
1. Incidence of type 1 diabetes in children aged 0-14 years in Hungary 
1.1 With the overall incidence rate of 12.5 per 100000 per year, Hungary belongs to the 
medium incidence geographical regions. During 1989-2009 the background population of 
children aged below 15 years has dropped by a third, and at the same time the number of 
newly diagnosed children increased considerably by around 40 new cases per year in boys and 
20 new cases per year in girls, resulting a 2.4 fold increase in incidence of type 1 diabetes in 
Hungarian children. The most important finding of the present study was that the annual 
increase (3.6%) of type 1 diabetes during 1979-1998 has continued further at an even higher 
rate (5.3%) in the last 11 years with no evidence of levelling off. The increase follows a linear 
trend with random fluctuations 
1.2 Extrapolation of incidence rates would suggest that by 2030 the predicted number of new 
cases is 2460 but this change is not shared evenly between the age groups with incidence of 
type 1 diabetes in the youngest age group expected to increase by 3.5 times in both sexes 
compared with a factor of 2.5 in boys and 1.5 in girls in the oldest age group. Our model 
suggests that in 2030 the percentage distribution of new cases across the three age-groups will 
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be more uniform at 31% (0–4 years), 38% (5–9 years), and 31% (10–14 years), with the 
excess of new cases in the 5–9 year age range being most apparent in boys. 
2. Gender, age-group specific incidence 
2.1. Most populations worldwide have shown that males and females have a similar risk for 
developing the disease, concurring with our results. Although a slight female excess has 
previously been noted (1989-1998), in more recent years a male excess (but not significant) in 
the age standardised rate has become evident. The increases in incidence seen in the present 
study were evident in both genders, although with a difference between the sexes primarily 
explained by the lower rate of increase in the 10-14 yr old girls compared to boys. Boys 
showed faster rates of increase in incidence in all three age groups than did girls, but only in 
the oldest age-group was this difference significant. 
2.2. From the beginning of the study period our results demonstrated a greater relative 
increase in incidence in the youngest children (6.2%), particularly in boys, compared to the 
increase in 5-9 years old (4.9%) and 10-14 years old children (3.3%). In spite of the rapid 
increase of the 0-4 year-old age group, the incidence rates (total and sex-specific) remain 
lowest in the youngest children and highest in 10-14 year-old children. The difference in 
incidence among the age groups, however, seems to be diminishing; at the end of the study 
period the incidence in the 5 to 9 year age group has now reached that of the 10 to 14 year 
age group, particularly in females. 
3. Seasonality 
3.1 Our study confirms the well-known seasonality of type 1 diabetes at diagnosis with a peak 
during winter (January) and a trough during summer (June). Seasonal variation was most 
apparent in 10-14 year-old children and absent in youngest children, possibly due to a lower 
number of cases in this age group. 
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4. Regional differences in incidence 
4.1 Disease maps demonstrated marked geographical variation in incidence within Hungary. 
There were indications that counties in the Western part of Hungary tend to have higher 
incidence rates, while counties in the Eastern part had lower rates than the overall average, 
however the rate of increase failed to show any significant difference. 
4.2 Our observation could not confirm any association between population density and the 
incidence of type 1 diabetes. 
 
Continued registration of incidence is of paramount importance to recognize long term 
tendencies, which may provide clues to the environmental exposures behind these trends. 
Furthermore, appropriate planning of services and resources are necessary to meet the need 
for the increased number of children diagnosed with diabetes. The rising incidence has far 
reaching effects beyond the diabetes teams: in schools, the community and other components 
of the healthcare system that these children use currently and in the future. 
 
 
II. CLINICAL CHARACTERISTICS OF TYPE 1 DIABETES AT TIME OF DIAGNOSIS 
IN HUNGARIAN CHILDREN 
1. Clinical and biochemical characteristics at time of diagnosis during 2002-2009 
1.1 The duration of clinical symptoms in type 1 diabetes is short, about 14 days and one third 
of the children were reported to have symptoms for less than 7 days. Polyuria and polydipsia 
remain the most common symptoms noted in 89% of the children. The majority of children 
have no family history of type 1 diabetes. Biochemical characteristics at diagnosis were in 
agreement with those from other studies: the mean blood glucose level was 26.5±11.9 mmol/l, 
mean HbA1c was 11.9±2.6 % and mean pH 7.30±0.14. 
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1.2 The median duration of symptoms before diagnosis was longer in older children. The 
clinical symptoms at onset did not differ significantly between groups with regard to age and 
gender. A concomitant infection was more frequently observed in the youngest age group. 
Youngest children had gross hyperglycaemia with mean blood glucose close to 30 mmol/l, 
while HbA1c was lowest in children aged 0-4 years, indicating a shorter duration of 
hyperglycaemia in this age group. 
1.3 The clinical picture at diagnosis was comparable between the two youngest age groups 
and similar to the presenting symptoms in older children. The higher blood glucose and lower 
HbA1c was even more pronounced in children under 2 years of age. 
2. Diabetic ketoacidosis 
2.1 Overall 32% of children aged <15 years presented with ketoacidosis at the time of T1DM 
onset. In Hungary, the frequency of DKA is high and has not changed over the years despite 
the increase in incidence of T1DM. We have not found any regional differences in the 
prevalence of DKA among the counties. 
2.2 Our study showed an increased frequency and severity of DKA at presentation in the 
younger age groups and a reduction with increasing age. Nearly half of the young children 0-4 
years of age presented in DKA at diagnosis compared to about one third in children aged 10-
14 years. We observed a conspicuously severe clinical decompensation at onset of type 1 
diabetes in children less than 2 years of age; about 60% of them presented with diabetic 
ketoacidosis and one fourth presented with impaired consciousness. Patients with ketoacidosis 
at onset had a significantly lower BMI-SDS, higher mean blood glucose and mean HbA1c 
level and one-quarter of them had an acute infection at presentation. The occurrence of DKA 
was less frequent in children with a first degree relative of type 1 diabetes. 
2.3 We also sought to investigate factors that could be associated with a higher prevalence of 
DKA, such as age at onset, duration of symptoms, history of a preceding infection, history of 
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T1DM among first degree relatives, BMI-SDS and blood glucose at time of diagnosis. As 
expected, DKA was more prevalent in younger age groups. Our study showed that children <2 
years old had two times the risk of presenting in diabetic ketoacidosis as children aged 10-14 
years. This increased risk was not present at 5years of age. Furthermore, higher blood glucose, 
lower BMI-SDS and a history of infection were significantly associated with an increased risk 
of DKA. Neither a history of T1DM in a first-degree relative nor the duration of symptoms 
predicted a diagnosis of new-onset diabetes before progression to DKA. 
 
In Hungary despite considerable improvements in diabetes therapy, no significant decline was 
observed in the prevalence of onset DKA over the past 8 years. This finding suggests that the 
general public is still not familiar with the signs and symptoms of type 1 diabetes, parents seek 
medical attention late, and that can lead to more profound metabolic decompensation, 
especially in younger children. The unacceptably large proportion of diabetic children with a 
high blood glucose, glycated haemoglobin, dehydration and ketonuria indicate a relatively 
severe metabolic decompensation at the time of diagnosis and call for further improvement in 
the diagnostic acumen of the paediatric community, as well. The very young children, in whom 
clinical presentation is more acute and early diagnosis may be difficult are particularly 
vulnerable. 
From an epidemiological perspective, further improvements should be made in the educational 
programs to increase the sensitivity of parents, child carers and physicians to the early signs of 
hyperglycaemia. Only a higher level of public awareness can reduce the frequency and severity 
of DKA in children as it has already been proven by information campaigns promoted in Italian 
schools (123, 124). A similar campaign has started in Hungary with an article recently 
published (13
th
 April 2011) in NŐK LAPJA, the widely read weekly women’s magazine. 
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